RAPT Therapeutics Q1 EPS $(0.79) Beats $(0.81) Estimate
Portfolio Pulse from Benzinga Newsdesk
RAPT Therapeutics reported Q1 earnings with losses of $(0.79) per share, surpassing the consensus estimate of $(0.81) by 2.47%. This represents a 3.95% increase in losses compared to the same period last year.
May 09, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RAPT Therapeutics reported a smaller-than-expected loss per share for Q1, indicating a potential positive outlook despite increased losses year-over-year.
Beating earnings estimates typically has a positive impact on investor sentiment and can lead to a short-term increase in stock price. Despite the year-over-year increase in losses, the fact that RAPT outperformed analyst expectations may be viewed positively by the market.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100